Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesStocksEarnInstitutionAI & More
Femasys Receives AMA CPT Editorial Panel Approval for New Category III CPT Code for FemaSeed Intratubal Insemination

Femasys Receives AMA CPT Editorial Panel Approval for New Category III CPT Code for FemaSeed Intratubal Insemination

FinvizFinviz2026/02/23 14:03
By:Finviz

-- Advances reimbursement strategy in the U.S. for FemaSeed, an intended first-step infertility treatment --

ATLANTA, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a leading biomedical innovator making fertility and non-surgical permanent birth control more accessible and cost-effective to women worldwide, announced today that it has received notice from the American Medical Association (AMA) CPT Editorial Panel approving a new, unique Category III Current Procedural Terminology (CPT) code covering the use of FemaSeed for intratubal insemination (ITI), a procedure that delivers sperm directly into the fallopian tube where conception occurs. The approved Category III CPT code is expected to be issued publicly by the AMA with an effective date of January 1, 2027. Approval of this Category III CPT code represents an important step in advancing the reimbursement strategy for FemaSeed to support broader clinical adoption, provider utilization, and expanded patient access to this first-step infertility treatment option.

“The creation of a new Category III code for the FemaSeed ITI procedure reflects the innovation and differentiated approach of our technology,” said Kathy Lee-Sepsick, Chief Executive Officer and Founder of Femasys Inc. “As we initiate the rollout of FemaSeed to gynecologists and their clinical teams, supported by the availability of our FemSperm

®
product line, we intend to expand our provider footprint, accelerate adoption, and increase access to care for more than 10 million women in the U.S. affected by infertility. Together, these offerings advance our scalable commercialization strategy and position us for sustainable long-term growth.”

FemaSeed is a next-generation artificial insemination solution that enhances fertilization by precisely delivering sperm to the fallopian tube, the natural site of conception. Developed to bridge the gap between traditional intrauterine insemination (IUI), which often has low success rates, and in vitro fertilization (IVF), which is costly and invasive, FemaSeed offers a safe, effective, accessible, and cost-efficient first-line, in-office treatment option. In its pivotal clinical trial (NCT0468847), conducted in the challenging setting of low male sperm count, FemaSeed achieved more than double the pregnancy rates of IUI.

1
FemaSeed is authorized for use in the U.S., Europe, UK, Canada, and Israel. Learn more at

About Femasys
Femasys is a leading biomedical innovator focused on making fertility and non-surgical permanent birth control more accessible and cost-effective for women worldwide through its broad, patent-protected portfolio of novel, in-office therapeutic and diagnostic products. As a U.S. manufacturer with global regulatory approvals, Femasys is actively commercializing its lead product innovations in the U.S. and key international markets. Femasys’ fertility portfolio includes FemaSeed

®
Intratubal Insemination (ITI), a groundbreaking first-step infertility treatment; FemSperm
®
, a CLIA waived sperm preparation and analysis product line; and FemVue
®
, a companion diagnostic for fallopian tube assessment. Published clinical trial data demonstrate that FemaSeed achieved more than double the pregnancy rates of traditional IUI, with a comparable safety profile and high patient and practitioner satisfaction.
1

FemBloc

®
permanent birth control is the first and only non-surgical, in-office alternative to centuries-old surgical sterilization that received full regulatory approval in Europe in June of 2025, the UK in August 2025, and New Zealand in September 2025. Commercialization of this highly cost-effective, convenient and significantly safer approach will be completed through strategic partnerships in select European countries. Alongside FemBloc, the FemChec
®
, diagnostic product provides an ultrasound-based test to confirm procedural success. Published data from initial clinical trials demonstrated compelling effectiveness, five-year safety, and high patient and practitioner satisfaction.
2
For U.S. FDA approval, enrollment in the FINALE pivotal trial (NCT05977751) is on-going.

References

1
Liu, J. H., Glassner, M., Gracia, C. R., Johnstone, E. B., Schnell, V. L., Thomas, M. A., L. Morrison, Lee-Sepsick, K. (2024). FemaSeed Directional Intratubal Artificial Insemination for Couples with Male-Factor or Unexplained Infertility Associated with Low Male Sperm Count. J Gynecol Reprod Med, 8(2), 01-12. doi: 10.33140/JGRM.08.02.08.

2
Liu, J. H., Blumenthal, P. D., Castaño, P. M., Chudnoff, S. C., Gawron, L. M., Johnstone, E. B., Lee-Sepsick, K. (2025). FemBloc Non-Surgical Permanent Contraception for Occlusion of the Fallopian Tubes. J Gynecol Reprod Med, 9(1), 01-12. doi: 10.33140/JGRM.09.01.05.

0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

AI Infrastructure Stocks Shed $4.2 Trillion—Is the “Shovel Seller Feast” Over?

Since June, Caterpillar has dropped by 44%, and Oklo has plummeted by 49%. Analysts point to the root cause: investors have been speculating on traditional industrial stocks as growth stocks, resulting in severely overvalued prices. Another key factor behind the sell-off is the uncertainty of data center regulatory policies following the U.S. midterm elections. The fundamentals remain resilient—Caterpillar has a backlog of orders totaling $78 billion, and several companies have secured revenue growth through 2027.

华尔街见闻•2026/11/16 04:21
AI Infrastructure Stocks Shed $4.2 Trillion—Is the “Shovel Seller Feast” Over?

Johnson & Johnson (JNJ.US) plans to spend $3.4 billion to acquire Ollin, expanding its presence in the retinal disease treatment sector.

According to sources familiar with the matter, Johnson & Johnson may announce a deal as early as Monday to acquire Texas-based biotech company Ollin Biosciences for up to $3.4 billion.

智通财经•2026/11/16 04:10

As market forces battle each other, the yen is caught in a tug-of-war between bulls and bears! Goldman Sachs bets on a comeback while Morgan Stanley predicts a fall to 162

As the USD/JPY exchange rate approaches the key 160 level again, Morgan Stanley and Goldman Sachs have expressed sharply divergent views on the yen’s outlook. This highlights that forecasting the yen’s exchange rate is becoming increasingly challenging amid multiple conflicting forces.

智通财经•2026/11/16 03:46
As market forces battle each other, the yen is caught in a tug-of-war between bulls and bears! Goldman Sachs bets on a comeback while Morgan Stanley predicts a fall to 162

Morgan Stanley MUFG Securities: Four Major Tailwinds Support Japanese Stocks, Raising TOPIX Target to 4,800 Points

Morgan Stanley MUFG Securities maintains an overweight position in Japanese stocks globally and sets the TOPIX benchmark target at 4,800 points by the end of 2027.

智通财经•2026/11/16 03:36
Morgan Stanley MUFG Securities: Four Major Tailwinds Support Japanese Stocks, Raising TOPIX Target to 4,800 Points